Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.65 - $1.31 $24,891 - $50,165
-38,294 Reduced 3.34%
1,107,825 $1.06 Million
Q1 2023

May 15, 2023

SELL
$0.38 - $1.07 $47,715 - $134,357
-125,568 Reduced 9.87%
1,146,119 $859,000
Q4 2022

Feb 14, 2023

SELL
$0.32 - $0.52 $77,088 - $125,269
-240,902 Reduced 15.93%
1,271,687 $470,000
Q3 2022

Nov 14, 2022

SELL
$0.43 - $1.56 $116,316 - $421,986
-270,504 Reduced 15.17%
1,512,589 $650,000
Q2 2022

Oct 27, 2022

BUY
$0.7 - $1.4 $88,074 - $176,149
125,821 Added 7.59%
1,783,093 $1.39 Million
Q2 2022

Aug 15, 2022

BUY
$0.7 - $1.4 $88,074 - $176,149
125,821 Added 7.59%
1,783,093 $1.39 Million
Q1 2022

Oct 27, 2022

SELL
$0.63 - $1.59 $79,267 - $200,055
-125,821 Reduced 7.06%
1,657,272 $2.14 Million
Q1 2022

May 13, 2022

SELL
$0.63 - $1.59 $687,347 - $1.73 Million
-1,091,027 Reduced 39.7%
1,657,272 $2.14 Million
Q4 2021

Feb 14, 2022

BUY
$1.27 - $2.42 $1.31 Million - $2.5 Million
1,031,749 Added 60.11%
2,748,299 $3.49 Million
Q3 2021

Nov 15, 2021

BUY
$2.15 - $3.82 $3.69 Million - $6.56 Million
1,716,550 New
1,716,550 $3.74 Million

Others Institutions Holding SPPI

# of Institutions
1
Shares Held
115K
Call Options Held
0
Put Options Held
0

About SPECTRUM PHARMACEUTICALS INC


  • Ticker SPPI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,164,000
  • Description
  • Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...
More about SPPI
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.